Rapid analysis of outcomes using the systemic anti-cancer therapy (SACT) dataset.
Authors
Pathak, RWallington, M
Saunders, C
Braun, Michael S
Mullamitha, Saifee A
Wilson, Gregory
Hasan, Jurjees
Dodwell, D
Bomb, M
Saunders, Mark P
Affiliation
University of Manchester, Manchester, UK.Issue Date
2017-03-17
Metadata
Show full item recordAbstract
We audited the accuracy of the Systemic Anti-Cancer Therapy dataset as a resource for rapid analysis of outcomes for patients, in this example, receiving Cancer Drug Fund funded monoclonal antibodies to treat metastatic colorectal cancer. We concluded that the Systemic Anti-Cancer Therapy dataset is a potentially valuable resource for rapidly determining survival outcome for patients treated with chemotherapy.Citation
Rapid analysis of outcomes using the systemic anti-cancer therapy (SACT) dataset. 2017, Clin OncolJournal
Clinical OncologyDOI
10.1016/j.clon.2017.02.011PubMed ID
28320583Type
ArticleLanguage
enISSN
1433-2981ae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2017.02.011
Scopus Count
Collections
Related articles
- Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
- Authors: Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C
- Issue date: 2017 Jun 20
- Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
- Authors: Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F
- Issue date: 2016 Feb 23
- Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
- Authors: Price T, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Guan X, Peeters M
- Issue date: 2016 Nov
- Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
- Authors: Jaka A, Gutiérrez-Rivera A, López-Pestaña A, del Alcázar E, Zubizarreta J, Vildosola S, Arregui MA, Sarasqueta C, Lobo C, Tuneu A
- Issue date: 2015 Jul-Aug
- High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab.
- Authors: Kumar SS, Tomita Y, Wrin J, Bruhn M, Swalling A, Mohammed M, Price TJ, Hardingham JE
- Issue date: 2017 Jun